TY - T1的富有同情心的高度耐药结核病患者中使用bedaquiline在孟买,印度JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01699 -2016欧元六世- 49 - 3 SP - 1601699 AU Udwadia Zarir f . AU - Ganatra Shashank AU - Mullerpattan Jai b Y1 - 2017/03/01 UR - //www.qdcxjkg.com/content/49/3/1601699.abstract N2 - bedaquiline,分枝杆菌ATP合酶抑制剂[1],是第一个结核病(TB)新药近50年。到目前为止,超过800病人收到全球药物通过同情使用(铜)项目。耐药结核病已成为全球公共卫生重点[2]和结核菌株被报道水平增加的阻力,比如那些耐多药耐药(MDR),广泛耐药(XDR)和[2 - 4]。印度熊的世界上最大的MDR病例[2]和惊人的模式经常会遇到阻力的在孟买等城市热点,包括第一个印度的情况下对所有一线和二线药物药物(sld) [5]。世界各地的几项研究表明增加治疗后疗效的bedaquiline优化背景方案(obr) (6 - 8)。在这样的设置,新药像bedaquiline急需;然而,在印度访问他们已经被证明是一个挑战。的76个应用程序收到来自印度,不超过52个印度全国病人收到bedaquiline下铜项目(个人沟通:詹森制药、印度,8月2日,2016)。在P.D. Hinduja医院,一个大型私人医院在孟买,我们一直在治疗耐多药结核病患者过去二十年[9]。2013年1月至2015年9月27日患者耐药结核菌株bedaquiline被认为是。 Applications for all 27 patients were made to the Janssen pharmaceuticals CU programme and, of these, 20 were approved and bedaquiline was administered. The resulting cohort is the largest in India to have received bedaquiline (20 patients from a countrywide total of 52). Bedaquiline was considered for patients based on the clinical judgement of the treating physician and there was no consultation with any panel of experts or TB consilium at this stage.Bedaquiline is a promising new drug treatment for drug-resistant TB. Urgent access is required in selected centres http://ow.ly/o1l73074ugh ER -